ACROBiosystems’ high-quality recombinant antigen proteins and kit products are considered to be vital in expediting the research and development of anti-SARS-CoV-2 vaccines and drugs.
A series of kit products have been developed by ACROBiosystems using its high-quality SARS-CoV-2 antigen proteins to enhance the efficiency of developing anti-SARS-CoV-2 drugs and vaccines.
Such kit products comprise SARS-CoV-2 antibody titer serologic assay kits, inhibitor screening kits, antigen pre-coated plates and antigen detection kits. These products can be utilized for SARS-CoV-2 neutralizing antibody screening, antigen detection and antibody detection.
Accelerated progress towards vaccine efficacy detection
More and more people are getting vaccinated for safeguarding themselves against SARS-CoV-2; at the same time, the original wild-type virus has been mutating to achieve increased fitness that might help evade vaccine-induced immune surveillance.
In view of this “Red Queen”1 challenge, the extent of the strength of the present vaccine protection against the circulating and emerging variants of the virus is a major concern. Multiple neutralizing antibody tests have been created to assess the effectiveness of a vaccine against the wild-type virus, but there has been a lack of an essential assessment tool to execute this function against the variants.
Currently, the gap between what people have and what people need is closed by the successful development of neutralizing antibody titer kits developed particularly for three significant SARS-CoV-2 variants, namely B.1.1.7 (the UK variant), P.1 (Brazilian variant) and B.1.351 (South African variant).
Such kits are based on competitive ELISA assays to identify the existence of neutralizing or blocking antibodies in human serum that can particularly block the binding of mutated spike trimer or spike RBD protein to its human receptor ACE2. These kits feature verified high specificity and sensitivity and are easy to use under standard laboratory conditions. They can also be used to test several samples simultaneously.
Neutralizing antibody titer assay kit
Anti-SARS-CoV-2 neutralizing antibody titer serologic assay kit (RAS-N022)
Correlation analysis of RAS-N022 and FDA-approved ELISA kit (detection of neutralizing antibody in post-vaccination serum). Image Credit: ACROBiosystems
> Detection of neutralizing antibody in post-vaccination serum samples
Anti-SARS-COV-2 Neutralizing Antibody Titer Serologic Assay Kit based on WT RBD (Cat.# RAS-N022), B.1.1.7 RBD (Cat.# RAS-N028), B.1.351 RBD (Cat.# RAS-N031), P.1 RBD (Cat.# RAS-N034) are used to detect neutralizing antibodies in 56 post-vaccination serum samples in order to evaluate vaccine efficacy against SARS-CoV-2 Variants of Concerns (VOC). Image Credit: ACROBiosystems
> Detection of inhibiting the ability of neutralizing antibodies in blocking SARS-CoV-2 RBD/human ACE2 interaction
Anti-SARS-CoV-2 (B.1.1.7) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD) (Cat.No.RAS-N028) is used to detect the inhibition of SARS-CoV-2 RBD/human ACE2 interaction by anti-SARS-CoV-2 neutralizing antibodies Cat. No. S1N-M122, Cat. No. SPD-M128 and Cat. No. SPD-M180. As shown in the figure above, Cat. No. S1N-M122 is more potent than Cat. No. SPD-M128 and Cat. No. SPD-M180 in blocking SARS-CoV-2 RBD/human ACE2 interaction. Image Credit: ACROBiosystems
Anti-SARS-CoV-2 (B.1.351) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD) (Cat.No.RAS-N031) is used to detect the inhibition of SARS-CoV-2 RBD/human ACE2 interaction by anti-SARS-CoV-2 neutralizing antibodies Cat. No. S1N-M122, Cat. No. SPD-M128 and Cat. No. SPD-M180. As shown in the figure above, Cat. No. S1N-M122 is more potent than Cat. No. SPD-M128 and Cat. No. SPD-M180 in blocking SARS-CoV-2 RBD/human ACE2 interaction. Image Credit: ACROBiosystems
IgG/IgM/total antibody titer assay kit
Anti-SARS-CoV-2 antibody IgG titer serologic assay kit (Spike RBD) (RAS-T024)
Detection of Monoclonal Anti-SARS-CoV-2 Antibody, Human IgG1 titer by Indirect-ELISA Assay. Immobilized SARS-CoV-2 Spike RBD at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-SARS-CoV-2 Antibody, Human IgG1 in 1:400 human serum. Detection was performed using HRP-Anti-human IgG antibody with sensitivity of 98 ng/mL. Image Credit: ACROBiosystems
Anti-SARS-CoV-2 antibody IgG titer serologic assay kit (Spike Trimer) (RAS-T025)
Detection of Anti-SARS-CoV-2 Antibody, Human IgG1 titer by Indirect-ELISA Assay. Immobilized SARS-CoV-2 Spike Protein at 2 μg/mL (100 μL/well) can bind monoclonal Anti-SARS-CoV-2 Antibody, Human IgG1 in 1:400 human serum. Detection was performed using HRP-Anti-human IgG antibody with sensitivity of 48 ng/mL. Image Credit: ACROBiosystems
Antibody isotype assay kit
Anti-SARS-CoV-2 IgG1/IgG 2/IgG 3/IgG 4 titer serologic assay kit (S Protein RBD) (RAS-T014/RAS-T015/RAS-T016/RAS-T017)
Cross-validation data for antibody subtype detection. Image Credit: ACROBiosystems
Antigen titer assay kit
SARS-CoV-2 spike protein titer assay kit (RAS-A020)
This assay kit employs a standard sandwich-ELISA format, providing a rapid detection of SARS-CoV-2 Spike protein. The kit consists of pre-coated Anti-SARS-CoV-2 Spike Protein Antibody Microplate, SARS-CoV-2 Spike protein as Control, biotin-Anti-SARS-CoV-2 Spike protein antibody and HRP-Streptavidin. Detection is performed using HRP-Streptavidin with sensitivity of 200 pg/mL. Image Credit: ACROBiosystems
SARS-CoV-2 spike RBD titer assay kit (RAS-A021)
Detection mutant and wide type SARS-CoV-2 S protein RBD by ELISA Kit. Image Credit: ACROBiosystems